Vaccine Breakthrough Prevents Cancer Returning In Trial

A personalised cancer vaccine has delivered a potentially major breakthrough. Helping keep high-risk melanoma from returning when combined with an existing immunotherapy drug. Developed by Moderna and Merck/MSD, the vaccine, called Intismeran, was tested alongside Keytruda. It was tested in more than 1,000 patients after surgery. The early results are striking: compared with Keytruda alone,……